GlassScriptPhysician profile
Alison M Schaefer
NPI 1932198553
$3,724.90
in general payments reported to CMS, 2019-2025
25 companies · $1,566 in 2025
The $1,566 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $195 · 2022: $115 · 2023: $759 · 2024: $1,090 · 2025: $1,566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,366 · Education: $49.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,366.00 |
| Education | $49.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $735.84 | 2021-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $648.14 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $636.04 | 2021-2025 | Dupixent |
| Genzyme Corporation | $394.20 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $263.42 | 2023-2025 | |
| Ars Pharmaceuticals Operations, INC. | $138.54 | 2025 | Neffy |
| Genentech USA, INC. | $131.28 | 2021-2025 | Xolair |
| Amgen INC. | $127.04 | 2021-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $120.53 | 2023-2025 | Takhzyro, Cuvitru |
| Abbvie INC. | $94.51 | 2023-2024 | |
| Csl Behring | $59.44 | 2025 | Andembry, Haegarda |
| Boston Scientific Corporation | $53.70 | 2025 | Upsylon |
| Azurity Pharmaceuticals, INC. | $45.53 | 2025 | Alvesco |
| Leo Pharma INC. | $35.87 | 2023-2024 | Adbry |
| Pharming Healthcare, INC. | $29.44 | 2022-2024 | Ruconest |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $29.14 | 2024 | Orladeyo |
| Incyte Corporation | $24.28 | 2023 | Opzelura |
| Lilly USA, LLC | $23.30 | 2024 | Taltz, Ebglyss |
| Pfizer INC. | $22.06 | 2023 | |
| Optinose US, INC. | $20.56 | 2021 | |
| Kaleo, INC. | $20.33 | 2021 | |
| Merck Sharp & Dohme LLC | $19.55 | 2023 | |
| Ionis Pharmaceuticals, INC. | $18.88 | 2025 | Dawnzera |
| Blueprint Medicines Corporation | $18.11 | 2025 | Ayvakit |
| Cycle Pharmaceuticals INC | $15.17 | 2025 | Sajazir |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Schaefer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.